FT
ALNY icon

Fiduciary Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fiduciary Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
666
-17
-2% -$5.13K ﹤0.01% 877
2026
Q1 		$226K Buy
683
+3
+0.4% +$1.02K ﹤0.01% 813
2025
Q4 		$270K Buy
680
+7
+1% +$3.1K ﹤0.01% 750
2025
Q3 		$307K Hold
673
– – ﹤0.01% 700
2025
Q2 		$219K Buy
+673
New +$186K ﹤0.01% 781

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiduciary Trust's ALNY Position: Q2 2026 in Review

Fiduciary Trust reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.5% in Q2 2026, selling an estimated $5.13K and leaving 666 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #877.

Fiduciary Trust first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $307K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fiduciary Trust held 666 shares of Alnylam Pharmaceuticals worth $200K as of Q2 2026.
  • Fiduciary Trust sold 17 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.13K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Fiduciary Trust's portfolio in Q2 2026, its #877 holding.
  • Fiduciary Trust first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Fiduciary Trust's Alnylam Pharmaceuticals position peaked at $307K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.